Researchers develop new type of drug to kill non-Hodgkin lymphoma tumor cells
Three researchers who are recipients of a collaborative grant from the Samuel Waxman Cancer Research Foundation have developed a new type of drug designed to kill non-Hodgkin lymphoma tumor cells.
Celgene has presented data for three Phase II studies evaluating combination therapy with Revlimid and Rituximab in patients with indolent non-hodgkin's lymphoma during the 51st American Society of Hematology's annual meeting in New Orleans, LA.